Search
Daridorexant
go.drugbank.com/drugs/DB15031ApprovedInvestigationalConventional treatments for insomnia include drugs targeting gamma-aminobutyric acid type-A (GABA-A), serotonin, histamine, or melatonin receptors; however, undesirable side effects are frequently reported … Daridorexant, formerly known as nemorexant, is a selective dual orexin receptor antagonist used to treat insomnia.
Ibrutinib
go.drugbank.com/drugs/DB09053ApprovedInvestigationalIt is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. … Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase.
Synonyms: 1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-oneVitamin A
go.drugbank.com/drugs/DB00162ApprovedInvestigationalNutraceuticalVet approvedDietary vitamin A is derived from a variety of carotenoids found in plants. It is enriched in the liver, egg yolks, and the fat component of dairy products.
Synonyms: Vitamin A Alcohol, all-trans-vitamin A alcoholInternational brands: Chocola AAceclidine
go.drugbank.com/drugs/DB13262ApprovedAceclidine is a cholinergic muscarinic agonist which began marketing in Europe in the 1970s for the treatment of glaucoma. … [A274278] Aceclidine was approved the US FDA in July 2025 for the treatment of adult patients with presbyopia.[L53768]
Granisetron
go.drugbank.com/drugs/DB00889ApprovedInvestigationalA serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients.
Products: GRANI-DENK 1 MG/ ML- AMPOLLA DE 1 MLTrastuzumab deruxtecan
go.drugbank.com/drugs/DB14962ApprovedInvestigationalTrastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers. … [A188988] Trastuzumab deruxtecan was developed by Daiichi Sankyo in collaboration with AstraZeneca and was first approved by the FDA in 2019.[L10842]
Viloxazine
go.drugbank.com/drugs/DB09185ApprovedInvestigationalWithdrawnViloxazine is a selective norepinephrine reuptake inhibitor.[L41685] For decades, an immediate-release formulation of viloxazine has been used in Europe as an antidepressant. … In April 2021, an extended-release formulation of viloxazine under the brand name QELBREE was approved by the FDA for the treatment of attention deficit hyperactivity disorder (ADHD).[A247985]
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates, Monoamine Oxidase A InhibitorsInotuzumab ozogamicin
go.drugbank.com/drugs/DB05889ApprovedInvestigational[L938] A month later, inotuzumab ozogamicin was also approved by the FDA.[L50542] … [A20352] Inotuzumab ozogamicin was first approved by the European Commission in June 2017 for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Categories: Decreased DNA Integrity, P-glycoprotein substrates with a Narrow Therapeutic IndexNalmefene
go.drugbank.com/drugs/DB06230ApprovedInvestigationalWithdrawn[L1024] In Europe, nalmefene oral tablets are used to reduce alcohol consumption in adults with alcohol dependence. … Nalmefene, a 6-methylene analogue of [naltrexone], is an opioid receptor antagonist.
Nicorandil
go.drugbank.com/drugs/DB09220ApprovedInvestigationalWithdrawnNicorandil is an orally efficacious vasodilatory drug and antianginal agent marketed in the UK, Australia, most of Europe, India, Philippines, Japan, South Korea, and Taiwan. … It is not an approved drug by FDA. It is a niacinamide derivative that induces vasodilation of arterioles and large coronary arteries by activating potassium channels.